SCHEMBL19903845

SCHEMBL19903845

Cn1ccc2ccc(-c3ccc4ccccc4c3)cc21

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1D P28221 1/20 0.59
HSD11B1 P28845 1/20 0.50
CYP2A6 P11509 1/20 0.47
ESR1 P03372 1/20 0.46
ESR2 Q92731 1/20 0.46
KDM4E B2RXH2 1/20 0.45
NPC1 O15118 1/20 0.45
ALDH1A1 P00352 1/20 0.45
POLB P06746 1/20 0.45
MAPT P10636 1/20 0.45
RAB9A P51151 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
ALOX5 P09917 1/20 0.44
HSD17B1 P14061 1/20 0.43
HSD17B2 P37059 1/20 0.43
PRMT5 O14744 1/20 0.41
WDR77 Q9BQA1 1/20 0.41
GSTP1 P09211 1/20 0.41
PDE10A Q9Y233 1/20 0.41
CYP17A1 P05093 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17179248 0.89 HSD11B1 (0.58) HTR1DHSD11B1CYP2A6ESR1ESR2
SCHEMBL18029140 0.87 HSD11B1 (0.55) HTR1DHSD11B1CYP2A6ESR1ESR2
SCHEMBL21237213 0.79 FAAH (0.46) CYP2A6ESR2NPC1RAB9ASMN1; SMN2
SCHEMBL14363730 0.78 HSD11B1 (0.48) HTR1DHSD11B1CYP2A6NPC1FAAH
SCHEMBL18029231 0.76 HTR6 (0.60) HTR1DHSD11B1CYP2A6MAPTHTR6
SCHEMBL15028093 0.76 PRKCI (0.48) HSD11B1CYP2A6KDM4EALDH1A1MAPT
SCHEMBL5256926 0.76 HSD11B1 (0.69) HSD11B1CYP2A6HTR6FAAH
SCHEMBL30241674 0.76 HSD11B1 (0.69) HSD11B1CYP2A6HTR6FAAH
SCHEMBL5350949 0.75 ESR1 (0.67) HTR1DESR1ESR2KDM4ENPC1
SCHEMBL29812 0.75 CDK4 (0.56) HSD11B1CYP2A6KDM4EALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3911658-B1 METHOD FOR PREPARATION OF FLUORO ALKYLATED COMPOUNDS BY HOMOGENEOUS NI CATALYSIS ARXADA AG (CH) 2023-01-11 EP disclosed
US-11530175-B2 Method for preparation of fluoro alkylated compounds by homogeneous Ni catalysis ARXADA AG (CH) 2022-12-20 US disclosed
US-20220041530-A1 Method for Preparation of Fluoro Alkylated Compounds by Homogeneous NI Catalysis LONZA LTD (CH) 2022-02-10 US disclosed
EP-3215476-B1 METHOD FOR PREPARATION OF FLUORO, CHLORO AND FLUOROCHLORO ALKYLATED COMPOUNDS BY HOMOGENEOUS CATALYSIS LONZA AG (CH) 2018-02-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220041530-A1 Method for Preparation of Fluoro Alkylated Compounds by Homogeneous NI Catalysis ABL1, AFF2, NAF1 HTR1D 3181/4885HSD11B1 899/4885CYP2A6 252/4885
US-11530175-B2 Method for preparation of fluoro alkylated compounds by homogeneous Ni catalysis ABL1, AFF2, NAF1 HTR1D 3181/4885HSD11B1 899/4885CYP2A6 252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.